Zimbabwe has rejected a major US health deal worth 367 million US dollars (£272m) over five years because of the United States' demand for sensitive data.
This rejection became public following a internal memorandum from December was leaked, indicating that President Emmerson Mnangagwa felt the deal was "lopsided".
An official representative has since clarified that the US was seeking genetic material for research and commercial gain but was unwilling to share the benefits from future treatments.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged continued talks to reach a agreement suitable to all parties so the nation's vital HIV treatment initiative can continue.
Wider Context
This development follows a similar case in neighbouring Kenya, where a court blocked a similar deal with the US following legal challenges were filed about the security of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to enhance transparency and accountability.
As per statements, Sixteen African countries have to date agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership would have delivered significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment through US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no equivalent assurance of access to any medical innovations – like new medicines or tests – that might result from that provided information," his statement read.
"Effectively, our country would provide the raw materials for scientific discovery without any assurance that the end products would be accessible to our citizens should a future pandemic arise."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were upending structures previously set up via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with potential global health emergencies.
"This mechanism is designed to ensure that when a country contributes its data, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to develop them."
These objections over the US deal "are not meant as hostility towards the US," he added.
"We are open to ongoing discussions with our American counterparts on how subsequent co-operation could be designed in a way that respects the independence and dignity of both nations."
Health Experts Response
A leading public health body stated it acknowledged the official position, but recommended that negotiations must proceed since much of the country's HIV programmes relied on foreign aid.
"In cases where technical issues arise, including those relating to data governance or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," the group commented.
This impasse highlights the complex tensions between accepting crucial foreign assistance and safeguarding a country's data in an increasingly data-driven world.